Asunto(s)
Melanoma/epidemiología , Neoplasias Cutáneas/epidemiología , Adolescente , Edad de Inicio , Niño , Preescolar , Femenino , Humanos , Incidencia , Lactante , Recién Nacido , Masculino , Melanoma/patología , Factores de Riesgo , Programa de VERF/estadística & datos numéricos , Factores Sexuales , Piel/patología , Neoplasias Cutáneas/patología , Tasa de Supervivencia , Estados Unidos/epidemiología , Adulto JovenAsunto(s)
Máscaras/efectos adversos , Traumatismos Ocupacionales/prevención & control , Úlcera por Presión/prevención & control , Piel/lesiones , Vendajes , Emolientes/uso terapéutico , Humanos , Máscaras/normas , Salud Laboral , Traumatismos Ocupacionales/etiología , Úlcera por Presión/etiología , Siliconas/uso terapéutico , Crema para la Piel/uso terapéuticoRESUMEN
Innovation is important for the improvement of health care. A small grant innovation funding program was implemented by the Hospital for Sick Children(SickKids) for the Perioperative Services group, awarding relatively small funds (approximately $10 000) in order to stimulate innovation. Of 48 applications,26 (54.2%) different innovation projects were funded for a total allocation of $227 870. This program demonstrated the ability of small grants to stimulate many applications with novel ideas, a wide range of innovations and reasonable academic productivity.
Asunto(s)
Organización de la Financiación/economía , Hospitales Pediátricos/economía , Desarrollo de Programa/economía , Centros Médicos Académicos/economía , Humanos , Invenciones/economía , Innovación Organizacional/economíaAsunto(s)
Sistemas de Registro de Reacción Adversa a Medicamentos , Anticuerpos Monoclonales Humanizados/efectos adversos , Anticuerpos Monoclonales/efectos adversos , Enfermedades Inflamatorias del Intestino/inducido químicamente , Anticuerpos Monoclonales/uso terapéutico , Anticuerpos Monoclonales Humanizados/uso terapéutico , Australia , Canadá , Bases de Datos Factuales , Progresión de la Enfermedad , Femenino , Humanos , Enfermedades Inflamatorias del Intestino/fisiopatología , Masculino , Medición de RiesgoAsunto(s)
Aspirina/efectos adversos , Melanoma/inducido químicamente , Melanoma/epidemiología , Neoplasias Cutáneas/inducido químicamente , Neoplasias Cutáneas/epidemiología , Adulto , Sistemas de Registro de Reacción Adversa a Medicamentos , Anciano , Anciano de 80 o más Años , Aspirina/uso terapéutico , Estudios de Casos y Controles , Estudios de Cohortes , Intervalos de Confianza , Relación Dosis-Respuesta a Droga , Femenino , Humanos , Incidencia , Modelos Logísticos , Cuidados a Largo Plazo , Masculino , Melanoma/patología , Persona de Mediana Edad , Medición de Riesgo , Factores Sexuales , Neoplasias Cutáneas/patología , Tasa de Supervivencia , Estados Unidos/epidemiología , Población UrbanaAsunto(s)
Hepatitis B Crónica/epidemiología , Hepatitis C Crónica/epidemiología , Psoriasis/epidemiología , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Estudios de Casos y Controles , Comorbilidad , Estudios Transversales , Femenino , Humanos , Masculino , Persona de Mediana Edad , Prevalencia , Estados Unidos/epidemiología , Adulto JovenRESUMEN
BACKGROUND: It is known that malignant melanoma (MM) survivors are at increased risk of future primary MM. However, the risk for noncutaneous second primary malignancies (SPMs) is not as well-understood. METHODS: An observational study utilizing data from the Surveillance, Epidemiology, and End Results (SEER) database was performed, assessing data from patients diagnosed with primary cutaneous MM to measure overall, as well as specific, tumor type and risk of SPM. RESULTS: Of the 132,438 patients recruited in the study population (mean age 55.5 years; 54% male), 23,794 SPMs were observed (O) (18% of patients at a mean age of 68.8 years), while 17,923 SPMs were expected (E) to occur (O : E 1.33, 95% CI 1.31-1.34). Excluding cutaneous MM occurring as a new primary malignancy, there was a significantly increased risk for SPMs among cutaneous MM survivors for each of the following tumor types: eye and orbit melanoma, tracheal, thyroid, salivary gland, retroperitoneum, small intestine, kidney, lymphoid and hematopoietic system, lymphoma overall, non-Hodgkin lymphoma, lymphocytic leukemia overall, chronic lymphocytic leukemia, male genital system (including prostate), and breast. Certain gender-specific trends for SPMs were also detected. CONCLUSIONS: Patients with primary cutaneous MM are at increased risk for primary noncutaneous MM as well as noncutaneous SPMs that include numerous tumor types. Enhanced oncologic surveillance for a variety of tumor types in melanoma survivors is warranted.
Asunto(s)
Supervivientes de Cáncer/estadística & datos numéricos , Melanoma/complicaciones , Neoplasias Primarias Secundarias/epidemiología , Neoplasias Cutáneas/complicaciones , Anciano , Femenino , Humanos , Masculino , Melanoma/mortalidad , Persona de Mediana Edad , Medición de Riesgo/estadística & datos numéricos , Programa de VERF/estadística & datos numéricos , Neoplasias Cutáneas/mortalidad , Tasa de SupervivenciaRESUMEN
INTRODUCTION: Skin cancers, including both malignant melanoma (MM) and nonmelanoma skin cancer (NMSC), are the most commonly diagnosed cancers in the US. The incidence of both MM and NMSC continues to rise. AREAS COVERED: Current evidence for an association between four of the most commonly prescribed classes of drugs in the U.S. and risk for MM and NMSC is reported. Medline was searched (January 2000 to May 2017) for each drug in the classes and for 'basal cell carcinoma', 'squamous cell carcinoma', 'non-melanoma skin cancer', 'skin cancer' and 'melanoma'. Skin cancer risk information was reported for: tumor necrosis factor alpha inhibitors (TNF-αIs), angiotensin-receptor blockers (ARBs), phosphodiesterase type 5 inhibitors (PDE5Is) and 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA)-reductase inhibitors (statins). EXPERT OPINION: Since skin cancer risk is associated with all four classes of these commonly prescribed drugs that represent nearly 20% of the Top 100 drugs in the U.S., these important findings warrant enhanced education, especially for prescribers and those patients at high risk for skin cancer.